GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

Chiome Bioscience 4583.T · JPY

Health Care · Tokyo Stock Exchange · 🇯🇵 Japan

Compare

78

+5.41%

Close of 9 Nov 2026, in JPY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Chiome Bioscience

Its shares trade on Tokyo Stock Exchange under the ticker 4583.T. It has been listed since 20 December 2011. In the fiscal year to 31 December 2025, it reported revenue of ¥593.3m and a net loss of ¥982.8m. At that date it held total assets of ¥1.73bn and shareholders' equity of ¥1.12bn.

Chiome Bioscience, Inc. engages in the development and sale of antibody drugs through the Autonomous Diversifying Library (ADLib) system. The company is headquartered in Shibuya-Ku, Tokyo-To. The company went IPO on 2011-12-20. The firm operates in two business segments. The Drug Discovery segment is engaged in the research and development of specific antibodies based on new antigens and mechanisms and licensing to pharmaceutical companies. The Drug Discovery Support segment is engaged in development of lead antibodies for therapeutic drugs in collaborating with pharmaceutical companies in Japan and overseas.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Life Sciences Tools & Services
Listed since
20 Dec 2011
Employees
49

Leadership

Pay as last reported

  • Mr. Masamichi KoikePresident, Representative Director, since 2023
  • Mr. Arihiko BijohiraChief Financial Officer, Manager of Business Planning Office, Director, since 2016
  • Mr. Shose TaokaChief Director of Development, Director, since 2023
  • Mr. Haruhisa KubotaIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • The ADLib system enables the development of specific antibody drugs for various therapeutic applications.
  • The Drug Discovery segment licenses antibodies to pharmaceutical companies based on new antigens.
  • The company employs 49 full-time staff members dedicated to life sciences research activities.

Weaknesses

  • The firm operates with a small workforce of only 49 employees globally.
  • Revenue depends heavily on licensing deals within the Drug Discovery business segment.
  • The company lacks direct commercialization capabilities for its developed therapeutic drug candidates.

Opportunities

  • The Drug Discovery Support segment collaborates with pharmaceutical companies in Japan and overseas.
  • New antigens and mechanisms offer potential for expanding the antibody drug portfolio.
  • Global partnerships can increase the reach of the Autonomous Diversifying Library technology.

Threats

  • Competition in the life sciences tools sector may pressure licensing revenue streams.
  • Regulatory changes in Japan could impact the development of specific antibody drugs.
  • Reliance on pharmaceutical partners creates risks if collaboration agreements are not renewed.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.